Sarepta Therapeutics, Inc. Message Board
- Reply to
Fly On The Wall Linked MNKD With The Wrong Drug. That's Why Down. Buy Opportunity
by going1green •19 hours agowhen a mis print causes a drop it's buy opportunity
-
Fly On the Wall 6/17/13
News Breaks
June 18, 2013
15:14 EDT MNKD MannKind CFO says will consider partnering after examining data
MannKind CFO Matthew Pfeffer said the company has considered waiting to partner until after FDA makes approval determination for AFREZZA, but thinks "optimal" time to partner may be before approval decision is made. -
-
-
- Reply to
Good Point Shorts. Baker Bros. Buying at $14.50 Means Will Triple to $45++++
by thegreen_o •Jun 14, 2013 10:32 AMadding more everyday
- Reply to
ACAD Holds Worldwide Patent For Drug in US, Europe & Additional Countries. // linked
by theman111knows •Jun 5, 2013 5:55 PMdang !!!
-
he Street 6/11 By: Adam F
Baker Brothers, already the largest Acadia shareholder, disclosed an upsized 23 percent stake in the company last week. High-conviction stocks in the Baker Brothers portfolio -- think Seattle Genetics (SGEN_) and Pharmacyclics (PCYC_) -- tend to perform really well, sometimes regardless of near-term fundamentals.
Oh yeah, it's worth noting that Acadia has a potential blockbuster drug in pimavanserin, which will be submitted to FDA as a new treatment for Parkinson's disease psychosis near the end of 2014. - Reply to
FDA Is 100% Behind ACAD / FDA Says ACAD Has Enough Compelling Data. LINK
by fromnyjohn •Jun 8, 2013 6:31 PMgood post
-
will be hot blockbuster
-
The Fly On The Wall June 12, 2013
News Breaks
June 12, 2013
CLDX Celldex price target raised to $19 from $14 at Brean Capital. Brean Capital raised its price target on Celldex due to its strong clinical data and robust pipeline. Shares are Buy rated. -
no interest
-
going to tank
-
thanks
-
The Scottish Medicines Consortium completed its assessment of Vertex Pharmaceuticals' resubmission for Kalydeco and posted its advice to the SMC website on June 10. Following a resubmission, Kalydeco is not recommended for use within NHS Scotland, the body stated.
- Reply to
The Street : VRTX Sales of 10 Billion . Undervalued Now. Big Upside 6/13. READ
by going1green •Jun 11, 2013 2:27 PMjust got home and read article. Looks Like a buy here.
-
up to fast now